Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Receivables (2020 - 2025)

Biofrontera has reported Receivables over the past 6 years, most recently at $12.1 million for Q4 2025.

  • For Q4 2025, Receivables rose 13.9% year-over-year to $12.1 million; the TTM value through Dec 2025 reached $12.1 million, up 13.9%, while the annual FY2025 figure was $12.1 million, 13.9% up from the prior year.
  • Receivables for Q4 2025 was $12.1 million at Biofrontera, up from $3.0 million in the prior quarter.
  • Over five years, Receivables peaked at $13.9 million in Q1 2022 and troughed at $2.1 million in Q3 2021.
  • A 5-year average of $6.5 million and a median of $5.6 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: soared 271.4% in 2022 and later tumbled 52.78% in 2024.
  • Year by year, Receivables stood at $3.9 million in 2021, then skyrocketed by 163.85% to $10.2 million in 2022, then dropped by 22.31% to $8.0 million in 2023, then skyrocketed by 33.32% to $10.6 million in 2024, then grew by 13.9% to $12.1 million in 2025.
  • Business Quant data shows Receivables for BFRI at $12.1 million in Q4 2025, $3.0 million in Q3 2025, and $4.0 million in Q2 2025.